Stopped: The DMC terminated trial GLP\_2022C1P002 early, citing a no longer positive benefit risk ratio, very low recruitment (\<1 patient/year/site), no added patient risk, but no relevant advantages to justify continuing the study and potential risks of TIVA.
The goal of this clinical investigation is to learn about the use of a novel medical device, the SPIRION Laryngeal Pacemaker, in patients suffering from bilateral vocal fold paralysis (BVFP) and who have had at least one related surgery on one of their vocal folds. The main questions it aims to answer are: * Is the use of the device safe? * Does the device improve the participants ability to take a breath? Participants will be implanted with the SPIRION Laryngeal Pacemaker and the development of their symptoms will be observed for the following 2 years.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Device Safety
Timeframe: 12 Months
Device Performance - Respiration
Timeframe: 12 Months